title: Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study.
abstract: Patients with IgE multiple myeloma have poor prognosis. Due to the rarity of this condition, no standard treatment has been developed. As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Her myeloma responded well to VMP regimen. The results of this case report thus suggest that physicians may consider VMP regimen for use as the initial treatment for IgE myeloma.
authors.affiliation: Department of Hematology, Saitama Red Cross Hospital, 8-3-33 Kamiochiai, Chuo-ku, Saitama, Saitama, 338-8553, Japan, satouhi1-tky@umin.ac.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Sato
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Komiya
authors.forename: Shigeru
authors.initials: S
authors.lastname: Hoshino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000473:pathology; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007122:Immunoelectrophoresis; D007073:Immunoglobulin E / Q000097:blood*; D007150:Immunohistochemistry; D008727:Methotrexate / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000097:blood* / Q000188:drug therapy*; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D007073:Immunoglobulin E; D014750:Vincristine; D002945:Cisplatin; D008727:Methotrexate